Contemporary quality of life issues affecting gynecologic cancer survivors

Hematology/Oncology Clinics of North America

Volumn 26, Issue 1, 2012, Pages 169-194

  Carter, Jeanne ^a   Penson, Richard ^b   Barakat, Richard ^a   Wenzel, Lari ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy toxicities; Quality of life; Sexual function

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ALOPECIA; ANEMIA; BLADDER DISEASE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURGERY; CANCER SURVIVOR; CLINICAL TRIAL (TOPIC); COLON CANCER; COST EFFECTIVENESS ANALYSIS; EMOTIONAL STRESS; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GYNECOLOGIC CANCER; HUMAN; INTESTINE OBSTRUCTION; LAPAROSCOPIC SURGERY; LYMPHEDEMA; MINIMALLY INVASIVE SURGERY; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCTION; REVIEW; ROBOTICS; SEXUAL FUNCTION; SEXUALITY; URINARY TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; VAGINA CANCER; VULVA CANCER;

COMMUNICATION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INTESTINAL OBSTRUCTION; LYMPHEDEMA; PALLIATIVE CARE; QUALITY OF LIFE; REPRODUCTION; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SURVIVORS;

EID: 84855880105     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.11.001     Document Type: Review

References (215)

1. Jemal A., Siegel R., Xu J.Q., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Siegel R., Ward E., Brawley O., et al. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
3. Harris P.F., Remington P.L., Trentham-Dietz A., et al. Prevalence and treatment of menopausal symptoms among breast cancer survivors. JPain Symptom Manage 2002, 23(6):501-509.
4. Crandall C., Petersen L., Ganz P.A., et al. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004, 11(5):519-530.
5. Gupta P., Sturdee D.W., Palin S.L., et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006, 9(1):49-58.
6. Schover L.R. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. JClin Oncol 2008, 26(5):753-758.
7. Ganz P.A., Greendale G.A., Petersen L., et al. Breast cancer in younger women: reproductive and late health effects of treatment. JClin Oncol 2003, 21(22):4184-4193.
8. Carter J., Rowland K., Chi D., et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol 2005, 97(1):90-95.
9. Wenzel L., Cella D. Quality of life issues in gynecologic cancer. Principles and practices of gynecologic oncology 2005, 1333-1342. Lippincott, Williams & Wilkins, Philadelphia. 4th edition. W.J. Hoskins, C.A. Perez, R.C. Young (Eds.).
10. Wenzel L., Dogan-Ates A., Habbal R., et al. Defining and measuring reproductive concerns of female cancer survivors. JNatl Cancer Inst Monogr 2005, (34):94-98.
11. Greendale G.A., Petersen L., Zibecchi L., et al. Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 2001, 8(2):111-119.
12. Haskell S.G., Bean-Mayberry B., Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?. Menopause 2009, 16(3):494-499.
13. Matulonis U.A., Kornblith A., Lee H., et al. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer 2008, 18(6):1183-1193.
14. Carmack Taylor C.L., Basen-Engquist K., Shinn E.H., et al. Predictors of sexual functioning in ovarian cancer patients. JClin Oncol 2004, 22(5):881-889.
15. Greenwald H.P., McCorkle R. Sexuality and sexual function in long-term survivors of cervical cancer. JWomens Health 2008, 17(6):955-963.
16. Carter J., Sonoda Y., Baser R.E., et al. A2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol 2010, 119(2):358-365.
17. Greimel E.R., Winter R., Kapp K.S., et al. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 2009, 18(5):476-482.
18. Stafford L., Judd F. Partners of long-term gynaecologic cancer survivors: psychiatric morbidity, psychosexual outcomes and supportive care needs. Gynecol Oncol 2010, 118(3):268-273.
19. Likes W.M., Stegbauer C., Tillmanns T., et al. Pilot study of sexual function and quality of life after excision for vulvar intraepithelial neoplasia. JReprod Med 2007, 52(1):23-27.
20. Carpenter K.M., Fowler J.M., Maxwell G.L., et al. Social support among gynecologic cancer survivors. Ann Behav Med 2010, 39(1):79-90.
21. Levin A.O., Carpenter K.M., Fowler J.M., et al. Sexual morbidity associated with poorer psychological adjustment among gynecological cancer survivors. Int JGynecol Cancer 2010, 20(3):461-470.
22. Le T., Menard C., Samant R., et al. Longitudinal assessments of quality of life in endometrial cancer patients: effect of surgical approach and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75(3):795-802.
23. Kornblith A.B., Huang H.Q., Walker J.L., et al. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a gynecologic oncology group study. JClin Oncol 2009, 27(32):5337-5342.
24. Lindau S.T., Gavrilova N., Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol 2007, 106(2):413-418.
25. Canada A.L., Schover L.R. The psychosocial impact of interrupted childbearing inlong-term female cancer survivors. Psychooncology 2010, [Epub ahead of print].
26. Cella D., Fallowfield L.J. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008, 107(2):167-180.
27. Ganz P.A., Rowland J.H., Desmond K., et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. JClin Oncol 1998, 16(2):501-514.
28. Joffe H., Soares C.N., Thurston R.C., et al. Depression is associated with worse objectively and subjectively measured sleep, but not more frequent awakenings, in women with vasomotor symptoms. Menopause 2009, 16(4):671-679.
29. Williams R.E., Levine K.B., Kalilani L., et al. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas 2009, 62(2):153-159.
30. Carter J., Goldfrank D., Schover L.R. Simple strategies for vaginal health promotion in cancer survivors. JSex Med 2011, 8(2):549-559.
31. Brotto L.A., Heiman J.R., Goff B., et al. Apsychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch Sex Behav 2008, 37(2):317-329.
32. Likes W.M., Stegbauer C., Tillmanns T., et al. Correlates of sexual function following vulvar excision. Gynecol Oncol 2007, 105(3):600-603.
33. Bergmark K., Avall-Lundqvist E., Dickman P.W., et al. Vaginal changes and sexuality in women with a history of cervical cancer. NEngl J Med 1999, 340(18):1383-1389.
34. Jensen P.T., Groenvold M., Klee M.C., et al. Early-stage cervical carcinoma, radical hysterectomy, and sexual function: a longitudinal study. Cancer 2004, 100(1):97-106.
35. Pieterse Q.D., Maas C.P., ter Kuile M.M., et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. Int J Gynecol Cancer 2006, 16(3):1119-1129.
36. Ditto A., Martinelli F., Borreani C., et al. Quality of life and sexual, bladder, and intestinal dysfunctions after class III nerve-sparing and class II radical hysterectomies a questionnaire-based study. Int J Gynecol Cancer 2009, 19(5):953-957.
37. Carter J., Chi D.S., Abu-Rustum N., et al. Brief report: total pelvic exenteration: a retrospective clinical needs assessment. Psychooncology 2004, 13(2):125-131.
38. Maggioni A., Roviglione G., Landoni F., et al. Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. Gynecol Oncol 2009, 114(1):64-68.
39. Benn T., Brooks R.A., Zhang Q., et al. Pelvic exenteration in gynecologic oncology: a single institution study over 20 years. Gynecol Oncol 2011, 122(1):14-18.
40. Creutzberg C.L., van Putten W.L., Koper P.C., et al. The morbidity of treatment for patients with stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 2001, 51(5):1246-1255.
41. Nout R.A., Putter H., Jurgenliemk-Schulz I.M., et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. JClin Oncol 2009, 27(21):3547-3556.
42. Saibishkumar E.P., Patel F.D., Sharma S.C. Evaluation of late toxicities of patients with carcinoma of the cervix treated with radical radiotherapy: an audit from India. Clin Oncol (R Coll Radiol) 2006, 18(1):30-37.
43. Vistad I., Cvancarova M., Fossa S.D., et al. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?. Int J Radiat Oncol Biol Phys 2008, 71(5):1335-1342.
44. Flay L.D., Matthews J.H. The effects of radiotherapy and surgery on the sexual function of women treated for cervical-cancer. Int J Radiat Oncol Biol Phys 1995, 31(2):399-404.
45. Bruner D.W., Lanciano R., Keegan M., et al. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993, 27(4):825-830.
46. Jensen P.T., Groenvold M., Klee M.C., et al. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2003, 56(4):937-949.
47. Frumovitz M., Sun C.C., Schover L.R., et al. Quality of life and sexual functioning in cervical cancer survivors. JClin Oncol 2005, 23(30):7428-7436.
48. Keys H.M., Roberts J.A., Brunetto V.L., et al. Aphase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 92(3):744-751.
49. Alektiar K.M., Venkatraman E., Chi D.S., et al. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005, 62(1):111-117.
50. Petereit D.G., Tannehill S.P., Grosen E.A., et al. Outpatient vaginal cuff brachytherapy for endometrial cancer. Int J Gynecol Cancer 1999, 9(6):456-462.
51. Anderson J.M., Stea B., Hallum A.V., et al. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radiat Oncol Biol Phys 2000, 46(2):417-425.
52. MacLeod C., Fowler A., Duval P., et al. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. Int J Radiat Oncol Biol Phys 1998, 42(5):1033-1039.
53. Nout R.A., Smit V.T., Putter H., et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010, 375(9717):816-823.
54. Kumar V.J., Nin C.Y., Kuei L.Y., et al. Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer 2010, 20(4):564-569.
55. Flynn K.E., Smith M.A., Davis M.K. From physician to consumer: the effectiveness of strategies to manage health care utilization. Med Care Res Rev 2002, 59(4):455-481.
56. Stabile C., Barakat R., Abu-Rustum N., et al. Preliminary data-a survey of female cancer patients' preference for sexual health interventions. JSex Med 2011, 8:65-66.
57. Rogers M., Todd C. Information exchange in oncology outpatient clinics: source, valence and uncertainty. Psychooncology 2002, 11(4):336-345.
58. Hordern A.J., Street A.F. Communicating about patient sexuality and intimacy after cancer: mismatched expectations and unmet needs. Med J Aust 2007, 186(5):224-227.
59. Berman L., Berman J., Felder S., et al. Seeking help for sexual function complaints: what gynecologists need to know about the female patient's experience. Fertil Steril 2003, 79(3):572-576.
60. Shifren J.L., Johannes C.B., Monz B.U., et al. Help-seeking behavior of women with self-reported distressing sexual problems. JWomens Health 2009, 18(4):461-468.
61. Wiggins D.L., Wood R., Granai C.O., et al. Sex, intimacy, and the gynecologic oncologist: survey results of the New England Association of Gynecologic Oncologists (NEAGO). JPsychosoc Oncol 2007, 25(4):61-70.
62. Zachariae R., Pedersen C.G., Jensen A.B., et al. Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer 2003, 88(5):658-665.
63. Stead M.L., Brown J.M., Fallowfield L., et al. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer 2003, 88(5):666-671.
64. de Bock G.H., Bonnema J., Zwaan R.E., et al. Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer 2004, 90(6):1144-1150.
65. Rogausch A., Sigle J., Seibert A., et al. Feasibility and acceptance of electronic quality of life assessment in general practice: an implementation study. Health Qual Life Outcomes 2009, 7:51.
66. Detmar S.B., Muller M.J., Schornagel J.H., et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002, 288(23):3027-3034.
67. Carter J., Sonoda Y., Chi D.S., et al. Radical trachelectomy for cervical cancer: postoperative physical and emotional adjustment concerns. Gynecol Oncol 2008, 111(1):151-157.
68. Carter J., Raviv L., Sonoda Y., et al. Recovery issues of fertility-preserving surgery in patients with early-stage cervical cancer and a model for survivorship the physician checklist. Int J Gynecol Cancer 2011, 21(1):106-116.
69. Jeffery D.D., Tzeng J.P., Keefe F.J., et al. Initial report of the cancer patient-reported outcomes measurement information system (PROMIS) sexual function committee review of sexual function measures and domains used in oncology. Cancer 2009, 115(6):1142-1153.
70. Baser RE, Carter J, Li Y. Psychometric validation of the female sexual function index (FSFI) in cancer survivors. Cancer Res, in press.
71. Baser RE, Carter J, Li Y. Psychometric evaluation of a 6-item short form of the Female Sexual Function Index (FSFI) in a sample of cancer survivors. London, England: International Society for Quality of Life Research (ISOQOL) Annual Conference. Oct 27-30, 2010.
72. Isidori A.M., Pozza C., Esposito K., et al. Development and validation of a 6-item version of the Female Sexual Function Index (FSFI) as a diagnostic tool for female sexual dysfunction. JSex Med 2010, 7(3):1139-1146.
73. Flynn K.E., Jeffery D.D., Keefe F.J., et al. Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS (R)). Psychooncology 2011, 20(4):378-386.
74. Flynn K.E., Reese J.B., Jeffery D., et al. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology 2011, [Epub ahead of print].
75. Carter J. Cancer-related infertility. Gynecol Oncol 2005, 99(Suppl. 1):S122-S123.
76. Ganz P.A., Moinpour C.M., Pauler D.K., et al. Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group study 9133. JClin Oncol 2003, 21(18):3512-3519.
77. Duffy C.M., Allen S.M., Clark M.A. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. JClin Oncol 2005, 23(4):766-773.
78. Thewes B., Meiser B., Rickard J., et al. The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. Psychooncology 2003, 12(5):500-511.
79. Carter J., Sonoda Y., Abu-Rustum N.R. Reproductive concerns of women treated with radical trachelectomy for cervical cancer. Gynecol Oncol 2007, 105(1):13-16.
80. Gershenson D.M. Fertility-sparing surgery for malignancies in women. JNatl Cancer Inst Monogr 2005, (34):43-47.
81. Abu-Rustum N.R., Sonoda Y., Black D., et al. Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol 2006, 103(3):807-813.
82. Plante M., Gregoire J., Renaud M.C., et al. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011, 121(2):290-297.
83. Plante M. Vaginal radical trachelectomy: an update. Gynecol Oncol 2008, 111(Suppl. 2):S105-S110.
84. Abu-Rustum N.R., Neubauer N., Sonoda Y., et al. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol 2008, 111(2):261-264.
85. Lanowska M., Mangler M., Spek A., et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic lymphadenectomy: prospective study of 225 patients with early-stage cervical cancer. Int J Gynecol Cancer 2011, 21(8):1458-1464.
86. Sonoda Y., Abu-Rustum N.R., Gemignani M.L., et al. Afertility-sparing alternative to radical hysterectomy: how many patients may be eligible?. Gynecol Oncol 2004, 95(3):534-538.
87. Toubassi D., Himel D., Winton S., et al. The informational needs of newly diagnosed cervical cancer patients who will be receiving combined chemoradiation treatment. JCancer Educ 2006, 21(4):263-268.
88. Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol 2004, 117(2):132-137.
89. Kim Y.B., Holschneider C.H., Ghosh K., et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997, 79(2):320-327.
90. Mazzon I., Corrado G., Morricone D., et al. Reproductive preservation for treatment of stage IA endometrial cancer in a young woman: hysteroscopic resection. Int J Gynecol Cancer 2005, 15(5):974-978.
91. Vinker S., Shani A., Open M., et al. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate?. Eur J Obstet Gynecol Reprod Biol 1999, 83(1):63-65.
92. Wang C.B., Wang C.J., Huang H.J., et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002, 94(8):2192-2198.
93. Kurman R.J., Kaminski P.F., Norris H.J. The behavior of endometrial hyperplasia. A long-term study of " untreated" hyperplasia in 170 patients. Cancer 1985, 56(2):403-412.
94. Trimble C.L., Kauderer J., Zaino R., et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006, 106(4):812-819.
95. Leitao M.M., Chi D.S. Fertility-sparing options for patients with gynecologic malignancies. Oncologist 2005, 10(8):613-622.
96. Duska L.R., Garrett A., Rueda B.R., et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol 2001, 83(2):388-393.
97. Evans-Metcalf E.R., Brooks S.E., Reale F.R., et al. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998, 91(3):349-354.
98. Gitsch G., Hanzal E., Jensen D., et al. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995, 85(4):504-508.
99. Walsh C., Holschneider C., Hoang Y., et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 2005, 106(4):693-699.
100. Jadoul P., Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003, 80(6):1315-1324.
101. Lowe M.P., Cooper B.C., Sood A.K., et al. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol 2003, 91(3):569-572.
102. Niwa K., Tagami K., Lian Z., et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005, 112(3):317-320.
103. Low J.J., Perrin L.C., Crandon A.J., et al. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000, 89(2):391-398.
104. Zanetta G., Bonazzi C., Cantu M., et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. JClin Oncol 2001, 19(4):1015-1020.
105. Morice P., Camatte S., El Hassan J., et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001, 75(1):92-96.
106. Schilder J.M., Thompson A.M., DePriest P.D., et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002, 87(1):1-7.
107. Brown C., Dharmendra B., Barakat R. Preserving fertility in patients (Pts) with epithelial ovarian cancer (EOC): the role of conservative surgery in the treatment of early stage disease. Gynecol Oncol 2000, 76. [abstract #36], 240.
108. Savage P., Constenla D., Fisher C., et al. Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol) 1998, 10(4):242-245.
109. Rao G.G., Skinner E.N., Gehrig P.A., et al. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 2005, 98(2):263-266.
110. Cadron I., Leunen K., Van Gorp T., et al. Management of borderline ovarian neoplasms. JClin Oncol 2007, 25(20):2928-2937.
111. Noyes N., Knopman J.M., Long K., et al. Fertility considerations in the management of gynecologic malignancies. Gynecol Oncol 2011, 120(3):326-333.
112. Oktay K., Sonmezer M. Fertility issues and options in young women with cancer. Recent Results Cancer Res 2008, 178:203-224.
113. Sonmezer M., Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004, 10(3):251-266.
114. Rosen A. Third-party reproduction and adoption in cancer patients. JNatl Cancer Inst Monogr 2005, (34):91-93.
115. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503-511.
116. Schover L.R. Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. Med Pediatr Oncol 1999, 33(1):53-59.
117. Nunns D., Williamson K., Swaney L., et al. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial carcinoma. Int J Gynecol Cancer 2000, 10(3):233-238.
118. Fujiwara K., Kigawa J., Hasegawa K., et al. Effect of simple omentoplasty and omentopexy in the prevention of complications after pelvic lymphadenectomy. Int J Gynecol Cancer 2003, 13(1):61-66.
119. Abu-Rustum N.R., Alektiar K., Iasonos A., et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006, 103(2):714-718.
120. Panici P.B., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. JNatl Cancer Inst 2008, 100(23):1707-1716.
121. Walker J.L., Piedmonte M.R., Spirtos N.M., et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group study LAP2. JClin Oncol 2009, 27(32):5331-5336.
122. Carlson J.W., Kauderer J., Walker J.L., et al. Arandomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 110(1):76-82.
123. Ryan M., Stainton M.C., Jaconelli C., et al. The experience of lower limb lymphedema for women after treatment for gynecologic cancer. Oncol Nurs Forum 2003, 30(3):417-423.
124. Janda M., Obermair A., Cella D., et al. Vulvar cancer patients' quality of life: a qualitative assessment. Int J Gynecol Cancer 2004, 14(5):875-881.
125. Pereira de Godoy J.M., Braile D.M., de Fatima Godoy M., et al. Quality of life and peripheral lymphedema. Lymphology 2002, 35(2):72-75.
126. Cella D.F., Wiklund I., Shumaker S.A., et al. Integrating health-related quality of life into cross-national clinical trials. Qual Life Res 1993, 2(6):433-440.
127. Carter J., Raviv L., Appollo K., et al. Apilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. Gynecol Oncol 2010, 117(2):317-323.
128. Boggess J.F., Gehrig P.A., Cantrell L., et al. Acomparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol 2008, 199(4):360.e1-360.e9.
129. Mendivil A., Holloway R.W., Boggess J.F. Emergence of robotic assisted surgery in gynecologic oncology: American perspective. Gynecol Oncol 2009, 114(2):S24-S31.
130. duPont N.C., Chandrasekhar R., Wilding G., et al. Current trends in robot assisted surgery: a survey of gynecologic oncologists. Int J Med Robot 2010, 6(4):468-472.
131. Boggess J.F., Gehrig P.A., Cantrell L., et al. Acase-control study of robot-assisted type III radical hysterectomy with pelvic lymph node dissection compared with open radical hysterectomy. Am J Obstet Gynecol 2008, 199(4):357.e1-357.e7.
132. Barnett J.C., Judd J.P., Wu J.M., et al. Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. Obstet Gynecol 2010, 116(3):685-693.
133. Gervasoni J.E., Sbayi S., Cady B. Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol 2007, 14(9):2443-2462.
134. Zivanovic O., Khoury-Collado F., Abu-Rustum N.R., et al. Sentinel lymph node biopsy in the management of vulvar carcinoma, cervical cancer, and endometrial cancer. Oncologist 2009, 14(7):695-705.
135. Badger C., Preston N., Seers K., et al. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev 2004, 4. CD003141.
136. Werngrenelgstrom M., Lidman D. Lymphedema of the lower-extremities after surgery and radiotherapy for cancer of the cervix. Scand J Plast Reconstr Surg Hand Surg 1994, 28(4):289-293.
137. Bergmark K., Avall-Lundqvist E., Dickman P.W., et al. Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls. Int J Gynecol Cancer 2006, 16(3):1130-1139.
138. Gaarenstroom K.N., Kenter G.G., Trimbos J.B., et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 2003, 13(4):522-527.
139. Burak W.E., Hollenbeck S.T., Zervos E.E., et al. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002, 183(1):23-27.
140. Petrek J.A., Senie R.T., Peters M., et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001, 92(6):1368-1377.
141. Schrenk P., Rieger R., Shamiyeh A., et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000, 88(3):608-614.
142. Burke T.W., Stringer C.A., Gershenson D.M., et al. Radical wide excision and selective inguinal node dissection for squamous-cell carcinoma of the vulva. Gynecol Oncol 1990, 38(3):328-332.
143. Hacker N.F., Leuchter R.S., Berek J.S., et al. Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. Obstet Gynecol 1981, 58(5):574-579.
144. Roy M., Bouchard-Fortier G., Popa I., et al. Value of sentinel node mapping in cancer of the cervix. Gynecol Oncol 2011, 122(2):269-274.
145. Cormier B., Diaz J.P., Shih K., et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol 2011, 122(2):275-280.
146. American College of Obstetricians and Gynecologists ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists: management of endometrial cancer. Obstet Gynecol 2005, 65(106):413-425.
147. Chapman R.H., Berger M., Weinstein M.C., et al. When does quality-adjusting life-years matter in cost-effectiveness analysis?. Health Econ 2004, 13(5):429-436.
148. Gotay C.C., Korn E.L., McCabe M.S., et al. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. JNatl Cancer Inst 1992, 84(8):575-579.
149. Bodurka-Bevers D., Basen-Engquist K., Carmack C.L., et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 2000, 78(3 Pt 1):302-308.
150. Calman K.C. Quality of life in cancer patients: an hypothesis. JMed Ethics 1984, 10(3):124-127.
151. Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res 1993, 2(2):153-159.
152. Bottomley A. The cancer patient and quality of life. Oncologist 2002, 7(2):120-125.
153. Cella D. What do global quality-of-life questions really measure? Insights from Hobday etal and the " do something" rule. JClin Oncol 2003, 21(16):3178-3179. [author reply: 3179].
154. Bezjak A., Tu D., Bacon M., et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. JClin Oncol 2004, 22(22):4595-4603.
155. Greimel E.R., Bjelic-Radisic V., Pfisterer J., et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. JClin Oncol 2006, 24(4):579-586.
156. Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. JNatl Cancer Inst 2004, 96(22):1682-1691.
157. Gralla R.J. Silk purse in Atlanta: a commentary on SWOG 9509, an advanced non-small cell lung cancer trial. Oncologist 1999, 4(3):188-190.
158. Sehouli J., Stengel D., Oskay-Oezcelik G., et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. JClin Oncol 2008, 26(19):3176-3182.
159. Lederberg M., Fitchett G. Can you measure a sunbeam with a ruler?. Psychooncology 1999, 8:375-377.
160. Levine M.N., Ganz P.A. Beyond the development of quality-of-life instruments: where do we go from here?. JClin Oncol 2002, 20(9):2215-2216.
161. Browman G.P. Science, language, intuition, and the many meanings of quality of life. JClin Oncol 1999, 17(6):1651-1653.
162. Efficace F., Bottomley A., Osoba D., et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials. Does HRQOL evaluation in prostate cancer research inform clinical decision making?. JClin Oncol 2003, 21(18):3502-3511.
163. Wenzel L., Huang H.Q., Cella D., et al. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 110(1):60-64.
164. Huang H.Q., Brady M.F., Cella D., et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007, 17(2):387-393.
165. Ferrell B., Smith S.L., Cullinane C.A., et al. Psychological well being and quality of life in ovarian cancer survivors. Cancer 2003, 98(5):1061-1071.
166. Kornblith A.B., Thaler H.T., Wong G., et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995, 59(2):231-242.
167. Wenzel L, Monk B, Huang H, etal. Clinically meaningful quality-of-life changes in ovarian cancer: results from Gynecologic Oncology Group Clinical Trial 152. Paper presented at Quality of Life III: translating the science of quality-of-life assessment into clinical practice. An example-driven approach for practicing clinicians and clinical researchers. Scottsdale, AZ. November 28, 2011.
168. Goff B.A., Mandel L.S., Drescher C.W., et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007, 109(2):221-227.
169. Sandadi S., Frasure H., Broderick M., et al. The effect of sleep disturbance on quality of life in women with ovarian cancer. Gynecol Oncol 2011, 123(2):351-355.
170. von Gruenigen V.E., Huang H.Q., Gil K.M., et al. Acomparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. JPain Symptom Manage 2010, 39(5):839-846.
171. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. NEngl J Med 1996, 334(1):1-6.
172. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 7(Suppl. 5):20-28.
173. Markman M. Viewing ovarian cancer as a " chronic disease": what exactly does this mean?. Gynecol Oncol 2006, 100(2):229-230.
174. Rustin G.J., van der Burg M.E., Griffin C.L., et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010, 376(9747):1155-1163.
175. Gordon A.N., Tonda M., Sun S., et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95(1):1-8.
176. Donovan H.S., Hartenbach E.M., Method M.W. Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. Gynecol Oncol 2005, 99(2):404-411.
177. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. JClin Oncol 2003, 21(17):3194-3200.
178. Cella D., Paul D., Yount S., et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003, 21(4):526-535.
179. Jensen S.E., Rosenbloom S.K., Beaumont J.L., et al. Anew index of priority symptoms in advanced ovarian cancer. Gynecol Oncol 2011, 120(2):214-219.
180. Gelber R.D., Goldhirsch A., Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 1991, 114(8):621-628.
181. Hirte H., Vergote I.B., Jeffrey J.R., et al. Aphase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group study. Gynecol Oncol 2006, 102(2):300-308.
182. Markman M. Management of ovarian cancer. An impressive history of improvement in survival and quality of life. Oncology (Williston Park) 2006, 20(4):347-354. [discussion: 354, 357-348, 364 passim].
183. Doyle C., Crump M., Pintilie M., et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. JClin Oncol 2001, 19(5):1266-1274.
184. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361(9375):2099-2106.
185. Pignata S., De Placido S., Biamonte R., et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006, 6:5.
186. Dunton C.J. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 2002, 7(Suppl. 5):11-19.
187. Seiden M.V. Ovarian cancer. Oncologist 2001, 6(4):327-332.
188. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. NEngl J Med 1999, 340(15):1144-1153.
189. Hilpert F., Stahle A., Tome O., et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy: a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005, 13(10):797-805.
190. Lorusso D., Ferrandina G., Greggi S., et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14(7):1086-1093.
191. Annas G.J. Informed consent, cancer, and truth in prognosis. NEngl J Med 1994, 330(3):223-225.
192. Available at: Accessed October 4, 2011. http://www.cochrane.org/.
193. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. NEngl J Med 2006, 354(1):34-43.
194. Wenzel L.B., Huang H.Q., Armstrong D.K., et al. Health-related quality of life duringand after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. JClin Oncol 2007, 25(4):437-443.
195. Markman M. Challenging ovarian cancer: how can we improve quantity and quality of life?. MedGenMed 2002, 4(4):10.
196. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. JClin Oncol 2004, 22(11):2159-2166.
197. McQuellon R.P., Thaler H.T., Cella D., et al. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006, 101(2):296-304.
198. Bookman M.A., Brady M.F., McGuire W.P., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27(9):1419-1425.
199. Atkins M. Presented at Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. vol. 24, Plenary discussion; 2006.
200. Donnelly C.M., Blaney J.M., Lowe-Strong A., et al. Arandomised controlled trial testing the feasibility and efficacy of a physical activity behavioural change intervention in managing fatigue with gynaecological cancer survivors. Gynecol Oncol 2011, 122(3):618-624.
201. Pothuri B., Montemarano M., Gerardi M., et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 2005, 96(2):330-334.
202. Abu-Rustum N.R., Barakat R.R., Venkatraman E., et al. Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. Gynecol Oncol 1997, 64(3):493-495.
203. Matulonis U.A., Seiden M.V., Roche M., et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. JPain Symptom Manage 2005, 30(6):563-569.
204. Baron T.H. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. NEngl J Med 2001, 344(22):1681-1687.
205. Fries J.F., Bruce B., Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol 2005, 23(Suppl. 39):S53-S57.
206. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. JClin Oncol 1996, 14(6):1756-1764.
207. Dobrez D., Cella D., Pickard A.S., et al. Estimation of patient preference-based utility weights from the functional assessment of cancer therapy: general. Value Health 2007, 10(4):266-272.
208. Cohn D.E., Kim K.H., Resnick K.E., et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. JClin Oncol 2011, 29(10):1247-1251.
209. Doyle C., Stockler M., Pintilie M., et al. Resource implications of palliative chemotherapy for ovarian cancer. JClin Oncol 1997, 15(3):1000-1007.
210. Lewin S.N., Buttin B.M., Powell M.A., et al. Resource utilization for ovarian cancer patients at the end of life: how much is too much?. Gynecol Oncol 2005, 99(2):261-266.
211. Lang E.V., Benotsch E.G., Fick L.J., et al. Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 2000, 355(9214):1486-1490.
212. Lakusta C.M., Atkinson M.J., Robinson J.W., et al. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 2001, 81(3):490-495.
213. von Gruenigen V.E., Daly B.J. Treating ovarian cancer patients at the end of life: when should we stop?. Gynecol Oncol 2005, 99(2):255-256.
214. Takeuchi E.E., Keding A., Awad N., et al. Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication. JClin Oncol 2011, 29(21):2910-2917.
215. Kass L.R. L'Chaim and its limits: why not immortality?. First Things 2001, (113):17-24.